Design, synthesis, and cytotoxic evaluation of quinazoline derivatives bearing triazole-acetamides

Pedrood, Keyvan; Taayoshi, Fahimeh; Moazzam, Ali; Iraji, Aida; Yavari, Ali; Sajjadi-Jazi, MeySayed Mahmoud; Mohajeri, Seyed Mohammad Reza; Garmsiri, Nadia; Haghpanah, Vahid; Soleymanibadi, Meysam; Larijani, Bagher; Hamedifar, Haleh; Adibpour, Neda; Mahdavi, Mohammad

doi:10.1016/j.heliyon.2023.e13528

Cited by 4 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[69] Notably, compound 51 demonstrated potent inhibitory activity against SK-BR-3 (IC 50 = 10.16 μM) and HCC1806 (IC 50 = 10.66 μM) breast cancer cell lines, indicating its potential as a promising candidate for further development as an anticancer agent (Scheme 30). [73] The cytotoxic activities of all obtained compounds were evaluated against three human cancer cell lines, HCT-116, MCF-7, and HepG2, as well as a normal cell line, WRL-68, after 48 and 72 hours. The compound 55 (X = 4-OCH 3 and R=H) was found to be the most potent derivative against HCT-116 with IC 50 values of 10.72 and 5.33 μM after 48 and 72 hours, respectively, compared to doxorubicin with IC 50 values of 1.66 and 1.21 μM, respectively.…”

Section: Other Miscellaneous Reactionsmentioning

confidence: 99%

“…Mahdavi et al . designed and synthesized a new series of quinazoline‐based compounds containing triazole‐acetamides [73] . The cytotoxic activities of all obtained compounds were evaluated against three human cancer cell lines, HCT‐116, MCF‐7, and HepG2, as well as a normal cell line, WRL‐68, after 48 and 72 hours.…”

Section: Quinazoline Derivatives As Anticancer Agentsmentioning

confidence: 99%

See 1 more Smart Citation

An Updated Overview on the Synthesis and Anticancer Evaluation of Quinazoline Derivatives

Kaur

Ȧnand

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

Cancer, a leading global cause of death, necessitates the exploration of safer and more effective anticancer drugs due to the adverse side effects associated with current cytotoxic treatments. Quinazoline and its derivatives have emerged as a promising class of drugs with demonstrated efficacy against diverse tumor types. In light of these advancements, this comprehensive review aims to outline recent developments in the utilization of quinazoline derivatives as anticancer agents. Additionally, the article offers valuable insights into the potential for novel quinazoline derivatives to serve as future anticancer drugs. By delving into the structure‐activity relationship study, this review equips researchers with a thorough understanding necessary for designing a substantial number of impactful quinazoline compounds, which hold great potential in the treatment of various life‐threatening disorders.

show abstract

Section: Other Miscellaneous Reactionsmentioning

confidence: 99%

Section: Quinazoline Derivatives As Anticancer Agentsmentioning

confidence: 99%

An Updated Overview on the Synthesis and Anticancer Evaluation of Quinazoline Derivatives

Kaur

Ȧnand

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

show abstract

“…11.32 µM, MTT assay) also displayed considerable antiproliferative activity against MCF-7 breast cancer cells. [86] The antiproliferative SAR of 1,2,3-triazole-thiazolidine-pyrido against MCF-7 breast cancer cells revealed that electron-donating group on the phenyl ring was favorable to the activity. [87] In and tamoxifen (IC 50 : 9.15 µM).…”

Section: 23-triazole-azole Hybridsmentioning

confidence: 99%

“…[ 85 ] Replacement of the amino linker between 1,2,3‐triazole and quinazoline moieties by ether linker was also tolerated, and hybrid 59 (IC 50 : 11.32 µM, MTT assay) also displayed considerable antiproliferative activity against MCF‐7 breast cancer cells. [ 86 ]…”

Section: 23‐triazole‐pyrimidine/quinazoline Hybridsmentioning

confidence: 99%

The anti‐breast cancer therapeutic potential of 1,2,3‐triazole‐containing hybrids

Song,

Zhang,

Zhang

et al. 2023

Archiv der Pharmazie

View full text Add to dashboard Cite

Breast cancer, as one of the most common invasive malignancies and the leading cause of cancer‐related deaths in women globally, poses a significant challenge in the world health system. Substantial advances in diagnosis and treatment have significantly improved the survival rate of breast cancer patients, but the number of incidences and deaths of breast cancer are projected to increase by 40% and 50%, respectively, by 2040. Chemotherapy is one of the principal treatments for breast cancer therapy, but multidrug resistance and severe side effects remain the major obstacles to the success of treatment. Hence, there is a vital need to develop novel chemotherapeutic agents to combat this deadly disease. 1,2,3‐Triazole, which can be effectively constructed by click chemistry, not only can serve as a linker to connect different anti‐breast cancer pharmacophores but also is a valuable pharmacophore with anti‐breast cancer potential and favorable properties such as hydrogen bonding, moderate dipole moment, and enhanced water solubility. Particularly, 1,2,3‐triazole‐containing hybrids have demonstrated promising in vitro and in vivo anti‐breast cancer potential against both drug‐sensitive and drug‐resistant forms and possessed excellent selectivity by targeting different biological pathways associated with breast cancer, representing privileged scaffolds for the discovery of novel anti‐breast cancer candidates. This review concentrates on the latest advancements of 1,2,3‐triazole‐containing hybrids with anti‐breast cancer potential, including work published between 2020 and the present. The structure–activity relationships (SARs) and mechanisms of action are also reviewed to shed light on the development of more effective and multitargeted candidates.

show abstract

Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study

El Hamaky,

Hamdi,

Bayoumi

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

Design, synthesis, and cytotoxic evaluation of quinazoline derivatives bearing triazole-acetamides

Cited by 4 publications

References 43 publications

An Updated Overview on the Synthesis and Anticancer Evaluation of Quinazoline Derivatives

An Updated Overview on the Synthesis and Anticancer Evaluation of Quinazoline Derivatives

The anti‐breast cancer therapeutic potential of 1,2,3‐triazole‐containing hybrids

Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study

Contact Info

Product

Resources

About